2024 Q3 Form 10-Q Financial Statement

#000164033424001302 Filed on August 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $675.00
YoY Change -100.0% -71.14%
Cost Of Revenue $0.00 $246.00
YoY Change -100.0% -71.02%
Gross Profit $0.00 -$429.00
YoY Change -100.0% -128.79%
Gross Profit Margin -63.56%
Selling, General & Admin $54.06K
YoY Change -4.76%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $121.9K $93.41K
YoY Change 25.89% 62.62%
Operating Profit -$121.9K -$92.98K
YoY Change 32.24% 66.18%
Interest Expense $9.697K $17.97K
YoY Change -52.98% -65.61%
% of Operating Profit
Other Income/Expense, Net $84.29K -$90.04K
YoY Change 6.49% 2.35%
Pretax Income -$183.0K
YoY Change 27.17%
Income Tax
% Of Pretax Income
Net Earnings -$37.65K -$183.0K
YoY Change 188.26% 27.17%
Net Earnings / Revenue -27113.63%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 1.232B shares 1.175B shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $240.00
YoY Change -99.4%
Cash & Equivalents $43.89K $235.00
Short-Term Investments
Other Short-Term Assets $2.500K
YoY Change
Inventory $0.00 $6.000K
Prepaid Expenses $0.00 $0.00
Receivables
Other Receivables
Total Short-Term Assets $46.39K $8.735K
YoY Change -71.48% -81.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $46.39K $8.735K
Total Long-Term Assets $0.00 $0.00
Total Assets $46.39K $8.735K
YoY Change -85.91% -81.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.280K
YoY Change 135.29%
Accrued Expenses $162.2K $152.8K
YoY Change 28.41% 10671.46%
Deferred Revenue
YoY Change
Short-Term Debt $349.8K
YoY Change -7.23%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.852M $1.930M
YoY Change 25.53% 11.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.852M $1.930M
Total Long-Term Liabilities $0.00
Total Liabilities $1.852M $1.930M
YoY Change 25.53% 11.79%
SHAREHOLDERS EQUITY
Retained Earnings -$8.792M -$8.754M
YoY Change 9.95% 9.66%
Common Stock $123.2K $123.2K
YoY Change 58.63% 113.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.805M -$1.922M
YoY Change
Total Liabilities & Shareholders Equity $46.39K $8.735K
YoY Change -85.91% -81.9%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$37.65K -$183.0K
YoY Change 188.26% 27.17%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$51.46K
YoY Change -9.51%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.10K
YoY Change -64.74%
NET CHANGE
Cash From Operating Activities -51.46K
Cash From Investing Activities
Cash From Financing Activities 32.10K
Net Change In Cash -19.36K
YoY Change -156.66%
FREE CASH FLOW
Cash From Operating Activities -$51.46K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
311000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
2.35 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0131 pure
bdpt Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm
P2Y
dei Entity Central Index Key
EntityCentralIndexKey
0001575142
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1231728974 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
895760225 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10000 shares
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Entity File Number
EntityFileNumber
000-54949
dei Entity Registrant Name
EntityRegistrantName
BioAdaptives Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2592228
dei Entity Address Address Line1
EntityAddressAddressLine1
2620 Regatta Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89128
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
659-8829
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1231728974 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60776 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
6000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
15281 usd
CY2024Q2 us-gaap Security Deposit
SecurityDeposit
2500 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
2500 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
8735 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
88557 usd
CY2024Q2 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
0 usd
CY2023Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
15441 usd
CY2024Q2 us-gaap Assets
Assets
8735 usd
CY2023Q4 us-gaap Assets
Assets
103998 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
458205 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
443579 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1122486 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
977872 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
311000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
321658 usd
CY2024Q2 us-gaap Notes Payable
NotesPayable
32096 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
0 usd
CY2024Q2 bdpt Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
6660 usd
CY2023Q4 bdpt Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
7520 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1930447 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1750629 usd
CY2024Q2 us-gaap Liabilities
Liabilities
1930447 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1750629 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
123173 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
89576 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6708259 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6527428 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8753869 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8264145 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1921712 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1646631 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8735 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103998 usd
CY2024Q2 us-gaap Revenues
Revenues
675 usd
CY2023Q2 us-gaap Revenues
Revenues
2339 usd
us-gaap Revenues
Revenues
12669 usd
us-gaap Revenues
Revenues
5715 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
246 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
849 usd
us-gaap Cost Of Revenue
CostOfRevenue
8639 usd
us-gaap Cost Of Revenue
CostOfRevenue
2245 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
-429 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
1490 usd
us-gaap Gross Profit
GrossProfit
-4030 usd
us-gaap Gross Profit
GrossProfit
3470 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4617 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14516 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36289 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26552 usd
CY2024Q2 us-gaap Professional Fees
ProfessionalFees
49438 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
42246 usd
us-gaap Professional Fees
ProfessionalFees
69290 usd
us-gaap Professional Fees
ProfessionalFees
50496 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
677 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19941 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1346 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
93407 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
57439 usd
us-gaap Operating Expenses
OperatingExpenses
146840 usd
us-gaap Operating Expenses
OperatingExpenses
78394 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-92978 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-55949 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-142810 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-74924 usd
CY2024Q2 us-gaap Other Income
OtherIncome
4950 usd
CY2023Q2 us-gaap Other Income
OtherIncome
0 usd
us-gaap Other Income
OtherIncome
4950 usd
us-gaap Other Income
OtherIncome
0 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-10 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-20 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
17969 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
52253 usd
us-gaap Interest Expense
InterestExpense
72584 usd
us-gaap Interest Expense
InterestExpense
103316 usd
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-77020 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-35705 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-279280 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-252844 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90039 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-87968 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-346914 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-356180 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-183017 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-143917 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-489724 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-431104 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-183017 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-143917 usd
us-gaap Net Income Loss
NetIncomeLoss
-489724 usd
us-gaap Net Income Loss
NetIncomeLoss
-431104 usd
CY2024Q2 bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
CY2023Q2 bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
CY2024Q2 bdpt Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
895760225 shares
CY2023Q2 bdpt Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
441742955 shares
bdpt Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
1105010656 shares
bdpt Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
355268125 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1646631 usd
CY2024Q1 bdpt Series A Preferred Stock Issued For License Fee Amount
SeriesAPreferredStockIssuedForLicenseFeeAmount
1500 usd
CY2024Q1 bdpt Series B Preferred Stock Issued For License Fee Amount
SeriesBPreferredStockIssuedForLicenseFeeAmount
3000 usd
CY2024Q1 bdpt Series B Preferred Stock Issued For Settlement Of Debt Amount
SeriesBPreferredStockIssuedForSettlementOfDebtAmount
1500 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
149455 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-306707 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1797883 usd
CY2024Q2 bdpt Series C Preferred Stock Issued For Purchase Of Inventory Amount
SeriesCPreferredStockIssuedForPurchaseOfInventoryAmount
6000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
53188 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-183017 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1921712 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1451501 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
108036 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-287187 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1630652 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
96057 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-143917 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1678512 usd
us-gaap Profit Loss
ProfitLoss
489724 usd
us-gaap Profit Loss
ProfitLoss
431104 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-279280 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-252844 usd
us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
18000 usd
us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
0 usd
us-gaap Impairment Of Investments
ImpairmentOfInvestments
21350 usd
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 usd
bdpt Amortization Of Other Intangible Assets
AmortizationOfOtherIntangibleAssets
1941 usd
bdpt Amortization Of Other Intangible Assets
AmortizationOfOtherIntangibleAssets
1346 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
52592 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
82385 usd
bdpt Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investment
UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestment
0 usd
bdpt Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investment
UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestment
-21 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6069 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2390 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
19993 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
15791 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92637 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76328 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
51044 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
32096 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
40000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32096 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91044 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-60541 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14716 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60776 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25405 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40121 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
bdpt Derivative Liability Recognized As Debt Discount
DerivativeLiabilityRecognizedAsDebtDiscount
0 usd
bdpt Derivative Liability Recognized As Debt Discount
DerivativeLiabilityRecognizedAsDebtDiscount
110000 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
202643 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
204093 usd
bdpt Series A Preferred Stock Issued For License Fee
SeriesAPreferredStockIssuedForLicenseFee
1500 usd
bdpt Series A Preferred Stock Issued For License Fee
SeriesAPreferredStockIssuedForLicenseFee
0 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 usd
bdpt Issuance Series C Preferred Stock For Purchase Of Inventory
IssuanceSeriesCPreferredStockForPurchaseOfInventory
6000 usd
bdpt Issuance Series C Preferred Stock For Purchase Of Inventory
IssuanceSeriesCPreferredStockForPurchaseOfInventory
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>

Files In Submission

Name View Source Status
0001640334-24-001302-index-headers.html Edgar Link pending
0001640334-24-001302-index.html Edgar Link pending
0001640334-24-001302.txt Edgar Link pending
0001640334-24-001302-xbrl.zip Edgar Link pending
bdpt-20240630.xsd Edgar Link pending
bdpt_10q.htm Edgar Link pending
bdpt_10qimg1.jpg Edgar Link pending
bdpt_ex311.htm Edgar Link pending
bdpt_ex312.htm Edgar Link pending
bdpt_ex321.htm Edgar Link pending
bdpt_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
bdpt-20240630_cal.xml Edgar Link unprocessable
bdpt-20240630_def.xml Edgar Link unprocessable
bdpt-20240630_pre.xml Edgar Link unprocessable
bdpt-20240630_lab.xml Edgar Link unprocessable
bdpt_10q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable